Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Traferox Technologies, INC.

Approvalsdevice change approved (PMA)30 Oct 2026

Traferox Technologies, INC.

30 Oct 2026: Device change approved (PMA) · TorEx Lung Perfusion System; TorEx Lung Perfusate. Recorded in the openFDA device PMA data.

View the source record

Decided
30 Oct 2026
Device
TorEx Lung Perfusion System; TorEx Lung Perfusate
Specialty
Gastroenterology, Urology
Type
Supplement (Normal 180 Day Track No User Fee)
Reason
Postapproval Study Protocol
Reference
P250025 S001
Location
Mississauga
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Traferox Technologies, INC.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Traferox Technologies, INC. in our registers.

More in Gastroenterology, Urology

PMA Approvals

See all

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.